Teva Pharmaceutical Industries Limited (TEVA)
Tevas Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
Tevas Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
📈 **POSITIVE** • High confidence analysis (82%) • Strong positive financial catalyst • High potential for stock growth **Sentiment:** Positive (87%) **Content type:** Financial